# Novo Nordisk A/S: Phase 1 study in Diabetes Mellitus, Type 2 (121 participants)

**Score:** 85/100

| Field | Value |
|---|---|
| Sponsor | Novo Nordisk A/S |
| Sponsor type | Industry (pharma, biotech, medtech) |
| Study | A Research Study to Check the Safety of NNC9836-0001 When Given to Healthy Participants and Participants With Type 2 Diabetes |
| NCT ID | NCT07896109 |
| Phase | Phase 1 |
| Status | not yet recruiting |
| Conditions | Diabetes Mellitus, Type 2 |
| Intervention types | drug |
| Target enrollment | 121 |
| Site countries | Germany |
| Posted | 2026-10-26 |
| Planned start | 2026-10-21 |
| Event | Newly registered study |
| Event date | 2026-10-26 |

## Why this score
- Posted in the last two weeks.
- Industry sponsor (buys outsourced services).
- 121 participants planned.
- Not yet recruiting: vendors still being chosen.

Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 (https://clinicaltrials.gov/study/NCT07896109). Last refreshed: 2026-11-04T06:04:38.232Z.
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.